等待开盘 04-02 09:30:00 美东时间
+1.090
+0.73%
U.S. RESEARCH ROUNDUP- Asana, PPG Industries, Verisign April 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Asana, PPG Industries and Verisign on Wednesday. HIGHLIGHTS * Asana Inc ASAN.N : RBC raises to sector perform
04-01 15:57
Diageo (DEO) pushed higher in premarket trading on Tuesday after Deutsche Bank boosted the spirits stock to a Buy rating after having it set at Hold. Analyst Mitch Collett said the upgrade was all abo...
03-31 19:29
今日重点评级关注:Oppenheimer:维持Alumis"跑赢大市"评级,目标价从50美元升至55美元;美银证券:维持Rocket Pharmaceuticals"买入"评级,目标价从8美元升至9美元
03-31 16:30
Deutsche Bank analyst Steve Powers maintains Constellation Brands (NYSE:STZ) with a Hold and lowers the price target from $162 to $154.
03-31 01:39
A potential $60B Pernod Ricard–Brown-Forman deal signals slowing demand plus rising pressure across alcohol stocks.
03-27 22:43
UPDATE 3-Pernod Ricard tie-up with Jack Daniel's maker would test family influence Pernod, Brown-Forman confirmed merger talks on Thursday Deal would deliver big cost savings Uniting powerful families could be tough Large premium may boost debt Deal will not fix growth problem, analysts say Adds com
03-27 17:08
BREAKINGVIEWS-Pernod and Jack Daniel’s would be a stiff cocktail The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Jeffrey Goldfarb NEW YORK, March 27 (Reuters Breakingviews) - Mixing anise liqueur and Tennessee whiskey would be a complex cocktail. There's some
03-27 08:27
BUZZ-US consumer, retail stocks up amid broader market rise ** Shares of U.S. retailers rise as risk appetite returned to markets after U.S. President Donald Trump said he had ordered the military to postpone strikes against Iranian power plants and energy infrastructure following "productive conver
03-23 22:43
Senator Markwayne Mullin owns 10 stocks in common with the investment portfolio of Berkshire Hathaway.
03-20 00:06
今日重点评级关注:花旗:维持Candel Therapeutics"买入"评级,目标价从22美元升至26美元;Chardan Capital:维持CervoMed"买入"评级,目标价从15美元升至21美元
03-19 14:31